Literature DB >> 6417095

Isolation and partial characterization of a cerulenin-sensitive mutant of Pseudomonas aeruginosa.

K Kawahara, K Uchida, K Aida.   

Abstract

Sensitivity of Pseudomonas aeruginosa to cerulenin was first tested. The result indicated that this bacterium is resistant to cerulenin. Cerulenin-sensitive mutants were isolated from P. aeruginosa PML 1552 by 1-methyl-3-nitro-1-nitrosoguanidine treatment and following carbenicillin plus D-cycloserine screening. Isolated mutants were designated CSM-1 to CSM-19, and some characters of CSM-19, which showed rapid growth almost as well as parent strain in the medium without cerulenin, were examined. The cell growth of CSM-19 was greatly inhibited by 50 micrograms/ml of cerulenin, but when the mixture of cellular fatty acids or both cis-vaccenic acid and palmitic acid were added to the medium, the growth was partially recovered. Incorporation of radioactivity into fatty acids from [1-14C]acetate was lowered by cerulenin. Those results mean that the fatty acid synthesis of CSM-19 was decreased by cerulenin. Although cellular fatty acid composition and amount were not notably different between CSM-19 and PML 1552, CSM-19 had less phosphatidylethanolamine, and more phosphatidylglycerol and cardiolipin than PML 1552. CSM-19 was also supersensitive to several other antibiotics, especially to carbenicillin and tetracycline, when compared with PML 1552, although both strains showed identical sensitivity to D-cycloserine, polymyxin B, and chloramphenicol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6417095     DOI: 10.7164/antibiotics.36.1329

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  1 in total

1.  Intrinsic resistance to inhibitors of fatty acid biosynthesis in Pseudomonas aeruginosa is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems.

Authors:  H P Schweizer
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.